Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Z Gastroenterol
; 58(9): 841-846, 2020 Sep.
Article
in En
| MEDLINE
| ID: mdl-32947629
ABSTRACT
Despite the high effectiveness of direct-acting antivirals for the treatment of hepatitis C, a small proportion of patients do not respond to approved regimens. The combination regimen of SOF/VEL/VOX was recently approved for patients with failure to prior NS5A-based treatment. In this German real-world cohort including patients with cirrhosis (27.3â%) and previous decompensation events, 12 weeks of SOF/VEL/VOX resulted in high virologic response rates irrespective of disease severity and prior DAA regimen. Adverse events were mostly mild or moderate and comparable to those seen in the approval studies.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Sulfonamides
/
Carbamates
/
Hepacivirus
/
Hepatitis C, Chronic
/
Macrocyclic Compounds
/
Sofosbuvir
/
Heterocyclic Compounds, 4 or More Rings
Limits:
Humans
Language:
En
Journal:
Z Gastroenterol
Year:
2020
Type:
Article
Affiliation country:
Germany